1. Fig. 2. Changes in glycosylated hemoglobin (HbA1c) levels
Fig. 2. Changes in glycosylated hemoglobin (HbA1c) levels. Changes in the HbA1c levels during acarbose add-on or metformin-switch therapy (A, baseline to week 16) and metformin, sitagliptin, and acarbose triple combination therapy (B, week 16 to 24). The mean±standard error values of the HbA1c levels (%) are plotted in line graphs with ‘a’ demonstrating P<0.05 compared to the HbA1c level in the Met+Sita group. The changes in the HbA1c levels (%) from the baseline to week 16 and from week 16 to 24 are plotted in the bar graphs. The between-group differences in the changes in the HbA1c from the baseline to week 16 and from week 16 to 24 were assessed by analysis of covariance using baseline HbA1c as a covariate. Met+Sita, the group treated with metformin, sitagliptin, and acarbose placebo; Met+Sita+Acarb, the group treated with metformin, sitagliptin, and acarbose; Sita+Acarb, the group treated with metformin placebo, sitagliptin and acarbose. aP<0.05 compared to baseline, bP<0.05 compared to the HbA1c change in the Met+Sita group.
Fig. 2. Changes in glycosylated hemoglobin (HbA1c) levels. Changes in the HbA1c levels during acarbose add-on or metformin- switch therapy (A, baseline to week 16) and metformin, sitagliptin, and acarbose triple combination therapy (B, week 16 to 24). The mean±standard error values of the…
Diabetes Metab J Jun;43(3):